With the advances in immunogenomics, the majority of tumor-specific antigens were found to be recognized by T helper cells (T(H)Cs). This observation led to the development of long epitope vaccines in various cancers. Mechanistically, we are still gaining a deeper understanding of the mode of action of T(H)Cs as precision antitumor agonists. Here, we discuss the specific cellular mechanisms of T(H)C functions in glioma immunology and contextualize current advances in anti-glioma …